The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Type I Interferons (IFNs) Regulate Tumor Necrosis Factor–related Apoptosis-inducing Ligand (TRAIL) Expression on Human T Cells: A Novel Mechanism for the Antitumor Effects of Type I IFNs
Open accessAbstract
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a proapoptotic member of the TNF family of type II membrane proteins, which constitutes one component of T cell cytotoxicity. In this study, we investigated the expression and function of TRAIL in human peripheral blood T (PBT) cells. Although freshly isolated PBT cells did not express a detectable level of TRAIL on their surface, a remarkable TRAIL expression was rapidly induced on the surface of both CD4+ and CD8+ PBT cells upon stimulation with anti-CD3 monoclonal antibody and type I interferons (IFNs). This enhancement of TRAIL expression was a unique feature of type I IFNs (IFN-α and IFN-β), and neither type II IFN (IFN-γ) nor various other cytokines enhanced TRAIL expression on anti-CD3–stimulated PBT cells. Type I IFNs have been used for clinical treatment of renal cell carcinomas (RCCs), and we found that most RCC cell lines were susceptible to TRAIL-induced apoptosis. Type I IFNs substantially augmented cytotoxic activity of anti-CD3–stimulated PBT cells against RCC cell lines in a TRAIL-dependent manner. These results indicate a unique feature of type I IFNs to regulate TRAIL-mediated T cell cytotoxicity, which may be involved in the antitumor effects of type I IFNs against various tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Darnell, J. E., Kerr, L. M., & Stark, G. R. (1994) · Science · doi:10.1126/science.8197455 · Cited by 6,080
Death Receptors: Signaling and Modulation
Ashkenazi, A., & Dixit, V. M. (1998) · Science · doi:10.1126/science.281.5381.1305 · Cited by 5,866 · cited 2×
“TRAIL-R4 carries a cytoplasmic domain containing a truncated death domain that cannot transmit a death signal but can activate nuclear factor k B, which may protect the cells from TRAIL-R1– or TRAIL-R2–induced apoptosis (9, 10).”
BackgroundNagata, S. (1997) · Cell · doi:10.1016/s0092-8674(00)81874-7 · Cited by 4,938
Identification and characterization of a new member of the TNF family that induces apoptosis
Wiley, S. R., Schooley, K., Smolak, P. J., Din, W. S., Huang, C.-P., Nicholl, J. K., Sutherland, G. R., Smith, T. D., Rauch, C., Smith, C. A., et al. (1995) · Immunity · doi:10.1016/1074-7613(95)90057-8 · Cited by 2,900
Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family
Pitti, R. M., Marsters, S. A., Ruppert, S., Donahue, C. J., Moore, A., & Ashkenazi, A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.22.12687 · Cited by 1,793
The Receptor for the Cytotoxic Ligand TRAIL
Pan, G., O'Rourke, K., Chinnaiyan, A. M., Gentz, R., Ebner, R., Ni, J., & Dixit, V. M. (1997) · Science · doi:10.1126/science.276.5309.111 · Cited by 1,767
Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors
Sheridan, J. P., Marsters, S. A., Pitti, R. M., Gurney, A., Skubatch, M., Baldwin, D., Ramakrishnan, L., Gray, C. L., Baker, K., Wood, W. I., et al. (1997) · Science · doi:10.1126/science.277.5327.818 · Cited by 1,664
Fas and Perforin Pathways as Major Mechanisms of T Cell-Mediated Cytotoxicity
Kägi, D., Vignaux, F., Ledermann, B., Bürki, K., Depraetere, V., Nagata, S., Hengartner, H., & Golstein, P. (1994) · Science · doi:10.1126/science.7518614 · Cited by 1,516
An Antagonist Decoy Receptor and a Death Domain-Containing Receptor for TRAIL
Pan, G., Ni, J., Wei, Y.-F., Yu, G.-L., Gentz, R., & Dixit, V. M. (1997) · Science · doi:10.1126/science.277.5327.815 · Cited by 1,496
Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways
Lowin, B., Hahne, M., Mattmann, C., & Tschopp, J. (1994) · Nature · doi:10.1038/370650a0 · Cited by 1,051
Metalloproteinase-mediated release of human Fas ligand.
Kayagaki, N., Kawasaki, A., Ebata, T., Ohmoto, H., Ikeda, S., Inoue, S., Yoshino, K., Okumura, K., & Yagita, H. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.6.1777 · Cited by 822
Self-citationDegli-Esposti, M. A., Dougall, W. C., Smolak, P. J., Waugh, J. Y., Smith, C. A., & Goodwin, R. G. (1997) · Immunity · doi:10.1016/s1074-7613(00)80399-4 · Cited by 821
Schneider, P., Holler, N., Bodmer, J.-L., Hahne, M., Frei, K., Fontana, A., & Tschopp, J. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.8.1205 · Cited by 812
(1986) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60034-2 · Cited by 800
Cytokine therapeutics: lessons from interferonalpha.
Gutterman, J. U. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.4.1198 · Cited by 703
Downregulation of Fas ligand by shedding
Tanaka, M., Itai, T., Adachi, M., & Nagata, S. (1998) · Nature Medicine · doi:10.1038/nm0198-031 · Cited by 669
Kägi, D., Ledermann, B., Bürki, K., Zinkernagel, R. M., & Hengartner, H. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.207 · Cited by 588
Romero, P., Rod Dunbar, P., Valmori, D., Pittet, M., Ogg, G. S., Rimoldi, D., Chen, J.-L., Liénard, D., Cerottini, J.-C., & Cerundolo, V. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.9.1641 · Cited by 521
Decreased tumor surveillance in perforin-deficient mice.
van den Broek, M. E., Kägi, D., Ossendorp, F., Toes, R., Vamvakas, S., Lutz, W. K., Melief, C. J., Zinkernagel, R. M., & Hengartner, H. (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.5.1781 · Cited by 512
Sheikh, M. S., Burns, T. F., Huang, Y., Wu, G. S., Amundson, S. A., Brooks, K., Fornace, A. J., & El‐Deiry, W. S. (1998) · PubMed · Cited by 428
Tsutsui, H., Nakanishi, K., Matsui, K., Higashino, K., Okamura, H., Miyazawa, Y., & Kaneda, K. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.9.3967 · Cited by 417
Kataoka, T., Shinohara, N., Takayama, H., Takaku, K., Kondo, S., Yonehara, S., & Nagai, K. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.156.10.3678 · Cited by 377
Thomas, W. D., & Hersey, P. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.5.2195 · Cited by 326
Immune Defence in Mice Lacking Type I and/or Type II Interferon Receptors
VAN DEN BROEK, M. F., MULLER, U., HUANG, S., ZINKERNAGEL, R. M., & AGUET, M. (1995) · Immunological Reviews · doi:10.1111/j.1600-065x.1995.tb00090.x · Cited by 306
Braun, M. Y., Lowin, B., French, L., Acha-Orbea, H., & Tschopp, J. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.2.657 · Cited by 297
Two distinct pathways of specific killing revealed by perforin mutant cytotoxic T lymphocytes
Kojima, H., Shinohara, N., Hanaoka, S., Someya-Shirota, Y., Takagaki, Y., Ohno, H., Saito, T., Katayama, T., Yagita, H., Okumura, K., et al. (1994) · Immunity · doi:10.1016/1074-7613(94)90066-3 · Cited by 290
Self-citationTRAIL/Apo-2-ligand-induced apoptosis in human T cells
Jeremias, I., Herr, I., Boehler, T., & Debatin, K.-M. (1998) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199801)28:01<143::aid-immu143>3.0.co;2-3 · Cited by 267
Involvement of TNF-Related Apoptosis-Inducing Ligand in Human CD4+ T Cell-Mediated Cytotoxicity
Kayagaki, N., Yamaguchi, N., Nakayama, M., Kawasaki, A., Akiba, H., Okumura, K., & Yagita, H. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.5.2639 · Cited by 231
Self-citationHattori, K., Hirano, T., Miyajima, H., Yamakawa, N., Tateno, M., Oshimi, K., Kayagaki, N., Yagita, H., & Okumura, K. (1998) · Blood · doi:10.1182/blood.v91.11.4051 · Cited by 217
Self-citationSpontaneous Development of Plasmacytoid Tumors in Mice with Defective Fas–Fas Ligand Interactions
Davidson, W. F., Giese, T., & Fredrickson, T. N. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.11.1825 · Cited by 189
Katsikis, P. D., Garcia-Ojeda, M. E., Torres-Roca, J. F., Tijoe, I. M., Smith, C. A., Herzenberg, L. A., & Herzenberg, L. A. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.8.1365 · Cited by 182
Contribution of Fas ligand to T cell-mediated hepatic injury in mice
Seino, K., Kayagaki, N., Takeda, K., Fukao, K., Okumura, K., & Yagita∥, H. (1997) · Gastroenterology · doi:10.1053/gast.1997.v113.pm9322527 · Cited by 142
Self-citationde Boer, M., Kasran, A., Kwekkeboom, J., Walter, H., Vandenberghe, P., & Ceuppens, J. L. (1993) · European Journal of Immunology · doi:10.1002/eji.1830231212 · Cited by 139
Ye, W., Young, J. D., & Liu, C.-C. (1996) · Cellular Immunology · doi:10.1006/cimm.1996.0293 · Cited by 78
Gresser, I. (1997) · Journal of Leukocyte Biology · doi:10.1002/jlb.61.5.567 · Cited by 63
Interferon Treatment of Human Neoplasia
(1986) · Advances in cancer research · doi:10.1016/s0065-230x(08)x6004-x · Cited by 39
Induction of G1 arrest by down-regulation of cyclin D3 in T cell hybridomas.
Miyatake, S., Nakano, H., Park, S. Y., Yamazaki, T., Takase, K., Matsushime, H., Kato, A., & Saito, T. (1995) · The Journal of Experimental Medicine · doi:10.1084/jem.182.2.401 · Cited by 31
Kaido, T. J., Maury, C., Schirrmacher, V., & Gresser, I. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910570417 · Cited by 26
Cytokine research: the interferon paradigm.
Morris, A. G., & Zvetkova, I. (1997) · Journal of Clinical Pathology · doi:10.1136/jcp.50.8.635 · Cited by 22
Tsutsui, T., Mu, J., Ogawa, M., Yu, W., Suda, T., Nagaga, S., Saji, F., Murata, Y., Fujiwara, H., & Hamaoka, T. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.159.6.2599 · Cited by 17
Cited by
Channappanavar, R., Fehr, A. R., Vijay, R., Mack, M., Zhao, J., Meyerholz, D. K., & Perlman, S. (2016) · Cell Host & Microbe · doi:10.1016/j.chom.2016.01.007 · Cited by 1,419
Targeting death and decoy receptors of the tumour-necrosis factor superfamily
Ashkenazi, A. (2002) · Nature Reviews Cancer · doi:10.1038/nrc821 · Cited by 1,360
Interferons at age 50: past, current and future impact on biomedicine
Borden, E. C., Sen, G. C., Uze, G., Silverman, R. H., Ransohoff, R. M., Foster, G. R., & Stark, G. R. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2422 · Cited by 1,154
Krug, A., Rothenfusser, S., Hornung, V., Jahrsdörfer, B., Blackwell, S., Ballas, Z. K., Endres, S., Krieg, A. M., & Hartmann, G. (2001) · European Journal of Immunology · doi:10.1002/1521-4141(200107)31:7<2154::aid-immu2154>3.0.co;2-u · Cited by 882
Apo2L/TRAIL and its death and decoy receptors
LeBlanc, H. N., & Ashkenazi, A. (2003) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401187 · Cited by 854
Metadata
- Authors
- Kayagaki, N., Yamaguchi, N., Nakayama, M., Eto, H., Okumura, K., & Yagita, H.
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 1999-05-03
- Volume
- 189
- Issue
- 9
- Pages
- 1451-1460
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2109510813
- Cited by
- 479
- References
- 40
- FWCI
- 10.89
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.